Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 16/20 | 0.78 |
| ▸ | FLT1 | P17948 | 3/20 | 0.56 |
| ▸ | FLT4 | P35916 | 3/20 | 0.56 |
| ▸ | TNNI3K | Q59H18 | 4/20 | 0.55 |
| ▸ | RET | P07949 | 1/20 | 0.54 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.54 |
| ▸ | KIT | P10721 | 1/20 | 0.54 |
| ▸ | RAF1 | P04049 | 1/20 | 0.51 |
| ▸ | MAP2K7 | O14733 | 3/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.50 |
| ▸ | BRAF | P15056 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4548793 | 0.91 | KDR (0.84) | KDRFLT1FLT4TNNI3KRET | |
| SCHEMBL2747767 | 0.90 | KDR (0.77) | KDRFLT1FLT4TNNI3KRET | |
| SCHEMBL4548796 | 0.89 | KDR (0.84) | KDRFLT1FLT4TNNI3KRET | |
| SCHEMBL4548798 | 0.88 | KDR (0.83) | KDRFLT1FLT4TNNI3KRET | |
| SCHEMBL4556267 | 0.88 | KDR (1.00) | KDRFLT1FLT4TNNI3KRAF1 | |
| SCHEMBL4548797 | 0.87 | KDR (0.84) | KDRFLT1FLT4TNNI3KRET | |
| SCHEMBL4548795 | 0.87 | KDR (0.75) | KDRFLT1FLT4TNNI3KRET | |
| SCHEMBL4548800 | 0.87 | KDR (0.75) | KDRFLT1FLT4TNNI3KRET | |
| SCHEMBL4548801 | 0.86 | KDR (0.80) | KDRFLT1FLT4TNNI3KRET | |
| SCHEMBL4548794 | 0.85 | KDR (0.73) | KDRFLT1FLT4TNNI3KRET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178557-B2 | Compounds and methods of use | AMGEN INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20090176774-A1 | Compounds and methods of use | AMGEN INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090176774-A1 | Compounds and methods of use | AMGEN INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-7435823-B2 | Compounds and methods of use | AMGEN INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-7435823-B2 | Compounds and methods of use | AMGEN INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-7435823-B2 | Compounds and methods of use | AMGEN INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-20060241115-A1 | Compounds and methods of use | AMGEN INC. | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241115-A1 | Compounds and methods of use | HGF, HGFAC, MET | KDR 354/4885FLT1 89/4885FLT4 125/4885 |
| US-20090176774-A1 | Compounds and methods of use | HGF, HGFAC, MET | KDR 354/4885FLT1 89/4885FLT4 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.